RVX
--------------------------------------------------------------------------------
…small-molecule trigger that stimulates production of native HDL.
------------------------------------------------------------------
How does it do that? T.i.a.
I only know what I can glean from Resverlogix web site and occasionally talking to IR.
There used to be a more detailed postulated mechanism on the website with cool graphics. The claim, as I recall, was the small molecule (RVX-208) acted as a mimetic, affecting a receptor that stimulates Apo A1 synthesis. From there, I think HDL and enhanced reverse cholesterol transport are believed to be subsequent, perhaps inevitable, metabolic steps.
The official blurb about the NexVas program (which includes RVX-208) describes the drug working as follows:
Our NexVas PR program has the capacity to become a leading force in the largest life science market in the world for the following reasons:
It is fundamentally different from other therapies focused on increasing HDL. Resverlogix’s small molecules have been shown to enhance the functionality of ApoA-I particles resulting in cholesterol excretion.
Resverlogix has taken the unique and physiological approach to pharmaceutical discovery by activating the body’s own health promoting genes (such as ApoA-I) to fight diseases.
This therapeutic approach of increasing the body’s endogenous ApoA-I production may avoid any immunologic complications associated with peptide or recombinant ApoA-I therapies currently in development, and more importantly facilitates continual enhancement of ApoA-I levels.
As an aside, RVX announced yesterday approval of its
US patent for RVX-208.
Market Data 
Markets 
AI
